tbuckley/cabot-search huggingface dataset:
GW26-e0732 Superior Dynamic Heart Rate Control and Non-Inferior Blood Pressure Control with Bisoprolol vs Metoprolol Sustained Release Tablet in Mild-to-Moderate Hypertension: CREATIVE Study
Authors: Tianlun Yang, Yuming Hao, Shuxian Zhou, Yinong Jiang, Xinjuan Xu, Baiming Qu, Xue Lin, Tianrong Ma, Bailing Luo, Hai Deng, Weiwei Liu
Journal: Journal of the American College of Cardiology (2015)
Diagnostic Role of Flow Cytometry Analysis of Bioptical Samples in the Diagnosis of Lymphoid Tumors
Authors: Lilla Cro, Andrea Ferrario, Nadia Zucal, Umberto Gianelli, Sonia Fabris, Lucia Nobili, Barbara Olivero, Francesca G Rossi, Luca Baldini, Giorgio Lambertenghi Deliliers
Journal: Blood (2008)
Logical inconsistency in comorbid health state preference assessment for prostate cancer
Authors: W. Dale, S. P. Bilir, J. Hemmerich, A. Basu, D. O. Meltzer
Journal: Journal of Clinical Oncology (2009)

6568 Background: With increasing need for efficient resource allocation, attention is turning to evidence-based decision making and cost-effectiveness analysis (CEA). Policy decisions depend on quality-adjusted outcomes from such analyses. Even small variations in the health state utilities used to quality adjust can have considerable effects, yet measuring utilities accurately is difficult. A particular challenge in the aging population with high cancer risk is maintaining logical consistency when evaluating comorbid utilities. We define this as ensuring that a single health state (SS) is rated no worse than a health state that adds another SS to that first one to make a comorbid health state (CS). Determining why or by whom this condition fails could improve elicitation practices and CEA for cancer and comorbid diseases. Methods: Men were surveyed at the time of prostate biopsy. SS and CS utility values were elicited via the time-trade off method. Demographic information, current health, and scores on anxiety subscales (HADS and MAX-PC) were collected also. The most prevalent health states associated with prostate cancer in the SEER database were chosen for assessment. CS were combinations of the SS “impotence” with each of incontinence, asymptomatic localized disease, and post-prostatectomy. Regression analysis showed the association of other survey elements to utility inconsistency. Mann-Whitney U-tests determined whether utility values differed by consistency. Results: 68% of respondents rated inconsistently at least once. Marriage and anxiety were correlated with rating inconsistently in univariate logistic analysis (p &lt; 0.01, p &lt; 0.05, respectively). Higher education was independently associated with more consistent answers (p &lt; 0.05). Inconsistent raters had significantly lower utility values for all SS, but not for CS (p &lt; 0.01). Conclusions: Over two thirds of men gave at least one logically inconsistent response across the three CS conditions. Being married, feeling anxious, and having less education were correlated with giving fewer consistent responses. Correcting these inconsistencies may change the results of quality-adjusted analyses. Strategies for eliciting more consistent responses are needed to accurately quality-adjust comorbid health states. No significant financial relationships to disclose.
A Single Center Comparison Between Two Different Apheresis Systems for Peripheral Blood Stem Cell Collections
Authors: Katharina Lisenko, Thomas Bruckner, Michael Hundemer, Anita Schmitt, Joe Puthenparambil, Petra Pavel, Jens Hillengass, Mathias Witzens-Harig, Hartmut Goldschmidt, Anthony D Ho, Patrick Wuchter
Journal: Blood (2015)
A phase II study of capecitabine plus oxaliplatin (XELOX) as first-line therapy for patients with advanced gastric cancer
Authors: Y. Park, J. Lee, B. Ryoo, M. Ryu, S. Yang, B. Kim, D. Shin, H. Chang, T. Kim, Y. Kang
Journal: Journal of Clinical Oncology (2006)

4079 Background: The combination chemotherapy of capecitabine and cisplatin showed considerable activity and good feasibility in patients with advanced gastric cancer. Oxaliplatin has a more favorable toxicity profile compared to cisplatin. The purpose of the study is to evaluate the efficacy and toxicity of capecitabine plus oxaliplatin combination chemotherapy in previously untreated patients with advanced gastric carcinoma. Methods: Patients received intravenous oxaliplatin 130 mg/m 2 over 2 hours on day 1 plus oral capecitabine 1000 mg/m 2 twice daily on days 1–14, every 3 weeks. Treatment was continued until progression of disease or intolerable toxicities with a maximum of 8 cycles. All the measurability and response evaluations were reviewed and confirmed by one investigator. Results: Total 54 patients were enrolled (37 men, 17 women). The median age was 57 years (range 29–70). Among these 54 patients, fifty-two patients were evaluable. A total 311 cycles of chemotherapy were delivered. The overall response rate was 63% (95% CI, 50–76%), with complete response in 2 patient and partial responses in 32 patients. After a median follow-up of 13 months, median progression-free survival was 5.8 months (95% CI, 4.4–7.2 months); median overall survival was 11.9 months (95% CI, 8.8–15.1 months). The treatment was generally well tolerated. The most common haematological adverse event was anaemia (70% of patients). Grade 3- 4 neutropenia was observed in 4 patients and neutropenic fever was experienced in only 1 patient. Four patients had G3 thrombocytopenia, which was accompanied by G3 gastrointestinal bleeding. The most common non-haematological toxicities were neuropathy (70%), vomiting (50%), diarrohea (33%), and hand-foot syndrome (39%). But, G3–4 toxicities were rare. There was one treatment related death which was associated with grade IV neutropenic sepsis. Conclusion: XELOX was active and well tolerated as a first-line therapy for advanced gastric carcinoma. No significant financial relationships to disclose.
The United States and Cuba — Turning Enemies into Partners for Health
Authors: C William Keck
Journal: New England Journal of Medicine (2016)

Interview with Dr. C. William Keck on an agreement between the United States and Cuba to cooperate on efforts to improve health. (10:10)Download The door has been opened for U.S.–Cuba collaboration aimed at preventing and controlling diseases that affect people in both countries. But though both populations could benefit from such efforts, the U.S. embargo against Cuba still presents a major barrier.
Pharmacokinetics- and Pharmacodynamics-Guided Optimization of the Dose and Treatment Schedule for the Dual SRC/ABL Inhibitor BMS-354825.
Authors: Feng Roger Luo, Zheng Yang, Amy Camuso, Richard Smykla, Stephen Castenada, Christine Flefleh, Krista Fager, Ivan Inigo, David Kan, Kelly McGlinchey, Mei-Li Wen, Robert Wild, Robert Borzilleri, Louis Lombardo, Robert Kramer, Francis Y. Lee
Journal: Blood (2004)
Abstract C14: Foxf1 transcription factor reprograms pulmonary endothelial cells to promote metastasis
Authors: Yuqi Cai, Tien Le, David Malewski, Craig Bolte, Chinmayee Goda, Tanya V. Kalin
Journal: Cancer Research (2016)

Abstract The ability to form a metastatic niche is a unique feature of tumor cells. The niche provides signals for tumor cells extravasation, survival, dormancy or proliferation, ultimately leading to the formation of metastasis. Endothelial cells of metastatic niche become activated and play a key role in tumor cells extravasation and establishing inflammatory microenvironment that supports metastatic outgrowth. Although multiple signaling pathways have been implicated in formation of metastatic niche, the transcriptional network which controls reprogramming of normal endothelial cells (EC) into activated endothelial cells of the metastatic niche (aEC) are poorly understood. Screening for multiple regulators of the endothelial reprogramming, we identified Forkhead Box F1 (Foxf1) transcription factor, which is highly expressed in normal pulmonary ECs and is down-regulated in aECs within mouse and human lung metastases. Tamoxifen-regulated inactivation of both Foxf1 alleles in EC of adult Pdgfb-CreER/Foxf1fl/fl mice caused lung inflammation and edema, leading to respiratory insufficiency and uniform mortality. Deletion of a single Foxf1 allele from mouse ECs was sufficient to increase the number and size of pulmonary metastases in the spontaneous orthotopic mouse model of breast cancer. Increased lung metastasis in Foxf1-deficient mice was associated with increased recruitment of macrophages to the metastatic niche. The genomic signature of Foxf1 deletion from purified lung ECs indicated increased expression of cell adhesion molecules and pro-inflammatory chemokines, as well as reduced expression of genes critical for maintenance of adherence junctions in ECs. Foxf1 knockdown in vitro and in vivo disrupted adherence junctions, increased endothelial permeability and decreased mRNA and protein levels of VE-cadherin, a key regulator of endothelial barrier function. Foxf1 directly bound to and induced transcriptional activity of the VE-cadherin (Cdh5) promoter through -788/-775 bp Cdh5 promoter region. Altogether, Foxf1 transcription factor controls reprogramming of normal pulmonary ECs into aECs of the metastatic niche by regulating expression of endothelial genes critical for recruitment of macrophages and extravasation of tumor cells through endothelial barrier. Citation Format: Yuqi Cai, Tien Le, David Malewski, Craig Bolte, Chinmayee Goda, Tanya V. Kalin. Foxf1 transcription factor reprograms pulmonary endothelial cells to promote metastasis. [abstract]. In: Proceedings of the AACR Special Conference: Function of Tumor Microenvironment in Cancer Progression; 2016 Jan 7–10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2016;76(15 Suppl):Abstract nr C14.
<i>Entering a Clinical Trial: Is It Right For You?</i>–A randomized study of the Clinical Trials Video and its impact on the informed consent process
Authors: S. Hitchcock-Bryan, B. Hoffner, S. Joffe, M. Powell, C. Parker, A. Wolanski, J. P. Eder, G. I. Shapiro, S. Bauer-Wu
Journal: Journal of Clinical Oncology (2007)

9072 Background: In an effort to improve the informed consent process for subjects considering participation in a clinical trial, we created an educational video: “Entering a Clinical Trial: Is it Right for You?” In this randomized study, we assessed the effect of the video on patients’ understanding and perceptions of clinical trials. We also assessed patient satisfaction with the video and how the video impacted decision-making and patient-provider communication. Methods: We recruited 90 adults considering cancer clinical trials of whom 77 participated. After discussing the trial with the physician and reading the trial consent form, patients were randomized to receive (n=38) or not receive (n=39) the study video. Using a validated questionnaire, we interviewed subjects to assess objective understanding of the trial, our primary endpoint, and self-reported understanding of clinical trials. All subjects completed a second interview assessing secondary endpoints, including patient-provider communication, satisfaction with video, and decision-making. We used linear regression (two-sided tests) to conduct the primary analysis and the Wilcoxon rank-sum test and descriptive statistics to analyze the secondary aims. Results: Neither objective nor self-reported understanding of clinical trials differed between the two groups (Mean 86.5 vs. 87, p=0.75). 85% (61/72) indicated the video was an important source of information about clinical trials; 89% of those who watched the video with their family/friends (n=37) said the video helped loved ones better understand clinical trials; 73% indicated it helped their family accept their decision about participation. 81% (58/72) felt better prepared to discuss the trial with their physician after watching the video. Of those who found the video helpful with decision- making, 80% (21/26) were considering a trial for the first time compared with 19% (5/26) veterans who had previously participated in a clinical trial. Conclusions: The video did not measurably improve subjects’ understanding of their clinical trials. However, subjects reported that the video was an important source of information, helped them educate their families, and enhanced patient-provider communication. No significant financial relationships to disclose.
A COMPARISON OF THE RATE OF ABSORPTION FROM NORMAL AND BURNED TISSUES
Authors: Edward C. Mason, Pearl Paxton, H. A. Shoemaker
Journal: Annals of Internal Medicine (1936)

ExcerptIn 1925, Mason, Davidson et al. published a series of papers,1, 2, 3recording the observations made on animals which died in 15 to 18 hours as a result of a small piece of liver tissue left free within the abdomen. While doing this work, we conceived the idea that death following burns was probably due to the same factors which caused the death of these animals. Davidson,4at the suggestion of Mason, introduced the tannic acid treatment of burns on the assumption that tannic acid would precipitate the dead and dying tissues and thereby prevent the absorption of toxic...
DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia
Authors: Mrinal M. Patnaik, Daniela Barraco, Terra L. Lasho, Christy M. Finke, Curtis A. Hanson, Rhett P. Ketterling, Naseema Gangat, Ayalew Tefferi
Journal: American Journal of Hematology (2016)

DNMT3A mutations are seen in ∼5% of patients with chronic myelomonocytic leukemia (CMML) and thus far, have had an indeterminate prognostic impact on survival. We carried out this study to assess the prognostic impact of DNMT3A mutations on a larger informative cohort of CMML patients (n = 261). DNMT3A mutations were seen in 6% (n = 16); 56% (n = 9) male, with a median age of 64 years. Eighty-one % of DNMT3A mutations were missense, with the Arg882 mutational hot spot accounting for 63% of all changes. Five (31%) patients had an abnormal karyotype whereas concurrent gene mutations (SF3B1/SRSF2/U2AF1-56%, TET2-50%, and ASXL1-25%) were seen in all patients. Apart from a higher frequency of SF3B1 (P = 0.0001) and PTPN11 (P = 0.005) mutations and a lower frequency of SRSF2 (P = 0.004) mutations, there were no significant differences between DNMT3A mutated patients and their wildtype counterparts. In univariate analysis, survival was shorter in DNMT3A mutated (median 8 months) versus wildtype (median 27 months) patients (P = 0.0007; HR 2.9, 95% CI 1.5-5.7); with other variables of significance including lower hemoglobin (P = 0.002), higher leukocyte count (P = 0.0009), higher monocyte count (P = 0.0012), circulating blast % (P = 0.001), circulating immature myeloid cells (P = 0.01), bone marrow blast % (P = 0.045), abnormal karyotype (P = 0.02), and ASXL1 (P = 0.01) mutations. In a multivariable model that included the aforementioned variables, when both DNMT3A and ASXL1 mutations were added, only DNMT3A (P < 0.0001) and ASXL1 (P = 0.004) mutations remained significant. DNMT3A mutations were also predictive of a shortened leukemia-free survival. These findings warrant inclusion of DNMT3A mutations in molecularly integrated CMML prognostic models. Am. J. Hematol. 92:56-61, 2017. © 2016 Wiley Periodicals, Inc.
Retrospective Cohort Analysis of Peripheral Arterial Occlusive Disease (PAOD) Events in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Authors: Francis J. Giles, Michael J. Mauro, Frank Hong, Christine-Elke Ortmann, Richard C. Woodman, Philipp D. LeCoutre, Giuseppe Saglio
Journal: Blood (2011)
Activating NOTCH1 Mutations Are Associated with Good Treatment Response in Childhood T-Cell Acute Lymphoblastic Leukemia.
Authors: Stephen Breit, Martin Stanulla, Thomas Flohr, Martin Schrappe, Wolf-Dieter Ludwig, Gabriele Tolle, Margit Happich, Martina M. Muckenthaler, Andreas E. Kulozik
Journal: Blood (2005)
Evaluating clinical trials: What exactly do medical oncologists know and use?
Authors: K. R. Hoffman, Kenneth R. Hoffman
Journal: Journal of Clinical Oncology (2010)

6152 Background: The correct evaluation and implementation of clinical trial data is essential for giving our patients the best treatment. Methods: Twenty eight medical oncologists participated in a study evaluating their knowledge of recently published clinical trials and then how they use this data in advising patients on treatment. Results: Part one of the study listed 15 studies involving breast, colon, non-small cell lung, renal cell carcinoma, diffuse large B-cell lymphoma, multiple myeloma and MDS. Using 80% (12/15) accuracy as a cut-off, 90% (25/28) of them knew which disease was being studied, 75% (21/28) knew which agents were being studied and 60% (16/28) correctly knew the stage or line of therapy. Only 50% (14/28) correctly identified which trials were phase II and phase III. In part two, the name, disease, stage of disease or line of therapy and drugs being studied was given and the oncologists were asked whether response rate (RR), progression-free survival (PFS) and/or overall survival (OS) were the primary endpoints. The study results were given and they were asked for their evalaution. Only 40% (11/28) were able to identify which of the studies had OS as a primary end point, while 80% (22/28) did get the quantitative difference between the treatment arms. In part 3 the physicians were asked to explain the meaning of statistical terms such as phase II vs. phase III, p-value, power, hazard ratio, trends vs. confidence level intervals and how they use of these terms making a treatment decision for their patient. Only a few of the oncologists understood the correct meaning of these statistical terms (9/28). Conclusions: Oncologists must have easy to understand summaries of pertainent clinical trial data when planning treatments for their patients. The information on the statistical vs clinical significance of these trial results must be provided. Oncologists are better in treating patients than in evaluating the data that lead to their treatment plan. Interestingly, 95% (26/28) of respondents felt that if a drug had a positive RR, PFS or OS than the patient, if appropriate, should be offered that treatment. Further study into how medical oncologists decide to treat their patients is warranted. No significant financial relationships to disclose.
Results of a Phase 1 Study of Quizartinib (AC220) As Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Remission Following Allogeneic Hematopoietic Cell Transplantation
Authors: Brenda M. Sandmaier, Samer K Khaled, Betul Oran, Guy Gammon, Denise Trone, Olga Frankfurt
Journal: Blood (2014)
AML with CBFB-MYH11 Rearrangement Is Characterized by RAS Pathway Alterations in 92% of Cases and Demonstrates a High Frequency of NF1 Deletions.
Authors: Claudia Haferlach, Frank Dicker, Alexander Kohlmann, Sonja Schindela, Tamara Weiss, Wolfgang Kern, Susanne Schnittger, Torsten Haferlach
Journal: Blood (2009)
LFB-R603, a Third-Generation Monoclonal Anti-CD20 Antibody Displays An Additive Antitumor Activity with Antileukemic Chemotherapeutic Agents in Mouse Xenograft Models
Authors: Isabel Tourais Esteves, Charles Dumontet, Stéphanie Herveau, Lina Reslan, Frédérique Brune, Laurence Van Overtvelt, Margarita Salcedo, Bénédicte Fournès
Journal: Blood (2011)
A phase I study of neoadjuvant paclitaxel/radiation in patients with potentially resectable adenocarcinoma of the pancreas
Authors: A. B. Chakravarthy, F. Y. Wu, C. D. Blanke, J. D. Berlin, R. D. Beauchamp, H. Choy, D. Delbeque
Journal: Journal of Clinical Oncology (2007)

15067 Background: To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of weekly paclitaxel when given with concurrent radiation in the neoadjuvant setting to patients with potentially resectable adenocarcinoma of the pancreas. A secondary goal was to assess the value of 18-fluoro-deoxy-glucose positron emission tomography (FDG-PET) as an early marker of therapeutic response. Methods: Patients received weekly paclitaxel, given as a 3-hour infusion, during the course of radiation. The starting dose of paclitaxel was 30 mg/m 2 /week. Doses were escalated in increments of 15 mg/m 2 in successive cohorts of 3–6 patients. Radiation therapy consisted of 45Gy in 25 fractions over 5 weeks. CT and PET scans were obtained prior to initiating treatment and one month following completion of chemoradiation. Results: Nine patients with resectable pancreatic cancer were enrolled through two dose levels. DLT was defined as grade 3 or greater. There were no DLTs at the first dose level of 30 mg/m 2 / week. DLTs consisted of nausea, neutropenia and hepatic toxicity developed at the second dose level of 45 mg/m 2 / week. Pre-treatment PET scans revealed uptake in all nine of the patients whereas pre-treatment CT scans detected disease in only 5 of 9 patients. Post-treatment PET scans correlated with pathologic findings in all 9 patients. Conclusions: The MTD for concurrent paclitaxel/radiation in the neoadjuvant setting was determined to be 30 mg/m 2 /week. DLTs were nausea, neutropenia and hepatic toxicity. FDG-PET may be superior to CT scans as a radiographic marker of treatment response. [Table: see text]
Use of illuminance as a guide to effective light delivery during daylight photodynamic therapy in the U.K.
Authors: P. O'Mahoney, M. Khazova, M. Higlett, T. Lister, S. Ibbotson, E. Eadie
Journal: British Journal of Dermatology (2016)

Daylight PDT (dPDT) is an effective and nearly painless treatment for field‐change actinic keratosis. Measuring the protoporphyrin‐IX (PpIX)‐weighted exposure dose can give an indication of when conditions are most viable for effective dPDT. It would be advantageous for practitioners if more detailed information of exposure dose and appropriate treatment conditions were available. Where sophisticated measurement equipment is unavailable, simpler and more cost‐effective methods of dose measurement are desirable. To devise a model whereby illuminance data can be converted into PpIX‐weighted exposure dose, and to use this model to estimate appropriate times for dPDT across the U.K. and Ireland. Spectral irradiance data were analysed to obtain a conversion model for illuminance to PpIX‐weighted dose. This model was applied to historic illuminance data from nine sites to obtain PpIX‐weighted dose across the U.K. and Ireland. Temperature data and an analysis of conservatory‐based dPDT were also considered. Distribution of the expected PpIX‐weighted dose across the nine locations is presented. Temperature data showed that it could be too cold for dPDT, even when there is sufficient light exposure. Conservatory‐based dPDT could extend the times in the year for possible treatment. This proposed conversion model provides a means of using an illuminance reading to calculate the PpIX‐weighted exposure dose. Dosimetry of dPDT may be carried out simply and at low cost using the presented method; however, the results presented may be used as a guide for those considering dPDT, without the need to conduct measurements themselves.
Mast Cell Disease and Blood Coagulation Abnormalities: Discussion on 14 Cases and Review of the Literature
Authors: Ana Carvalhosa, Gandhi Damaj, Danielle Canioni, Laure Cabaret, Nathalie Costédoat-Chalumeau, Pascal Cathebras, Stéphane Durupt, Isabelle Durieu, Emmanuel Gyan, David Launay, Benoit Pilmis, Laurent Frenzel, Olivier Lortholary, Olivier Hermine, Cedric R. Hermans, Marie-Olivia Chandesris
Journal: Blood (2014)